Anti-heparin-platelet factor 4 antibodies are associated with arterial and venous thrombosis in patients with maintenance haemodialysis

Ying Tan; Lei Cao; Ji-cheng Lv; Yu Yan; Li Zuo; Mei Wang; Lu Yu; Feng Yu; Ming-hui Zhao

doi:10.1160/TH09-05-0304

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(06): 1282-1284
DOI: 10.1160/TH09-05-0304

Letters to the Editor

Schattauer GmbH

Anti-heparin-platelet factor 4 antibodies are associated with arterial and venous thrombosis in patients with maintenance haemodialysis

Authors

Ying Tan^*

¹Renal Division, Department of Medicine, Peking University, First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China
Lei Cao^*

¹Renal Division, Department of Medicine, Peking University, First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China

²Department of Nephrology, PLA 305 Hospital; Beijing, P. R. China
Ji-cheng Lv

¹Renal Division, Department of Medicine, Peking University, First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China
Yu Yan

³Renal Division, Department of Medicine, Peking University People’s Hospital, Beijing, P. R. China
Li Zuo

¹Renal Division, Department of Medicine, Peking University, First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China
Mei Wang

³Renal Division, Department of Medicine, Peking University People’s Hospital, Beijing, P. R. China
Lu Yu

²Department of Nephrology, PLA 305 Hospital; Beijing, P. R. China
Feng Yu

¹Renal Division, Department of Medicine, Peking University, First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China
Ming-hui Zhao

¹Renal Division, Department of Medicine, Peking University, First Hospital; Institute of Nephrology, Peking University, Key laboratory of Renal Disease, Ministry of Health of China, Beijing, P. R. China

Abstract

Full Text

References

References
1 Chong BH, Castaldi PA. Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin-associated thrombocytopenia. Austr New Zeal J Med 1986; 16: 715-716.
2 Warkentin TE, Chong BH, Greinacher A. Heparininduced thrombocytopenia: towards consensus.[see comment]. Thromb Haemost 1998; 79: 1-7.
3 Pena de la, Vega L, Miller RS, Benda MM. et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study.[see comment]. Mayo Clin Proc 2005; 80: 995-1000.
4 Ahmad S, Untch B, Haas S. et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Mol Cell Biochem 2004; 258: 163-170.
5 Juhl D, Eichler P, Lubenow N. et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haemat 2006; 76: 420-426.
6 Warkentin TE, Sheppard JA, Moore JC. et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146: 341-346.
7 Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/ platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678-684.
8 Zwicker JI, Uhl L, Huang WY. et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.[see comment]. J Thromb Haemost 2004; 02: 2133-2137.
9 Jacobson SH, Egberg N, Hylander B. et al. Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002; 22: 42-47.
10 Carrier M, Rodger MA, Fergusson D. et al. Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int 2008; 73: 213-219.
11 Lee EY, Hwang KY, Yang JO. et al. Anti-heparinplatelet factor 4 antibody is a risk factor for vascular access obstruction in patients undergoing hemodialysis. J Korean Med Sci 2003; 18: 69-72.
12 Daneschvar HL, Seddighzadeh A, Piazza G. et al. Deep vein thrombosis in patients with chronic kidney disease. Thromb Haemost 2008; 99: 1035-1039.
13 Qureshi AR, Alvestrand A, Danielsson A. et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.[see comment]. Kidney Int 1998; 53: 773-782.
14 Kalantar-Zadeh K, Kilpatrick RD, Kuwae N. et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transpl 2005; 20: 1880-1888.
15 Rauova L, Poncz M, McKenzie SE. et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131-138.
16 Greinacher A, Gopinadhan M, Gunther JU. et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscl Thromb Vasc Biol 2006; 26: 2386-2393.
17 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. 4 ed.. New York: Informa Health-care USA; 2007
18 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.[see comment]. Thromb Haemost 1992; 68: 95-96.
19 Gruel Y, Boizard-Boval B, Wautier JL. Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia.[comment]. Thromb Haemost 1993; 70: 374-375.
20 Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfusion Med Rev 2006; 20: 259-272.
21 Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies--distinguishing “signal” from “noise”. Thromb Haemost 2008; 100: 523-524.